Drug Trial Radar · NCT05002127
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Jan 15, 2022
Primary completion
May 24, 2024
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma
Interventions
Evorpacept (ALX148)Drug
IV Q2W
TrastuzumabDrug
IV Q2W
RamucirumabDrug
IV Q2W
PaclitaxelDrug
IV Days 1, 8, and 15 of a 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2Time frame: Last randomized patient on study at least 16 weeks
- Phase 3Time frame: From the date of randomization to the date of death (due to any cause), up to 36 months postdose
Locations
83 sites in 12 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope & Innovation
Anaheim, California
University of California Los Angeles
Los Angeles, California
Vanderbilt University Medical Center
Nashville, Tennessee
NEXT Virginia
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Icon Cancer Centre Southport
Southport, Queensland, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Fakultní Nemocnice Hradec Králové
Hradec Králové, Czechia
Fakultní Nemocnice Olomouc
Olomouc, Czechia
Vseobecna Fakultni Nemocnice v Praze
Prague, Czechia
Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz
Besançon, France
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
Hôpital Morvan
Brest, France
Centre Léon Bérard
Lyon, France
Hôpital Privé Jean Mermoz
Lyon, France
Institut Paoli-Calmettes
Marseille, France
Hôpital Saint-Antoine
Paris, France
Hôpital Trousseau
Paris, France
Hôpital Rangueil
Toulouse, France
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi
Catania, Italy
Azienda Ospedaliero - Universitaria Careggi
Florence, Italy
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy
Policlinico Universitario Campus Bio-Medico
Roma, Italy
Azienda Sanitaria Universitaria Friuli Centrale - P.O. Santa Maria della Misericordia
Udine, Italy
National Cancer Center Hospital East
Chiba, Japan
Kyushu Cancer Center
Fukuoka, Japan
Gifu University Hospital
Gifu, Japan
Japanese Red Cross Kumamoto Hospital
Kumamoto, Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Japan
Nagasaki University Hospital
Nagasaki, Japan
Oita University Hospital - Hasama Campus
Ōita, Japan
Osaka Prefectural Hospital Organization - Osaka International Cancer Institute
Osaka, Japan
Kindai University Hospital
Osaka, Japan
Saitama Cancer Center
Saitama, Japan
Tohoku University Hospital
Sendai, Japan
Shizuoka Cancer Center
Shizuoka, Japan
National Cancer Center Hospital
Tokyo, Japan
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.